Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates. Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium. For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register. For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.
Patent details
1933869
Title:
Verwendung von IL-23 und IL-17 antagonisten zur behandlung von autoimmuner entzundlicher augenerkrankung
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic information
Application number:
068139450
WO application number:
US2006033840
Type:
European patent granted for BE
Status:
Revoked
Publication number:
1933869
WO publication number:
WO 2007/027761
1rst applicant's nationality:
Translation language:
German
EPO publication language:
English
SPC number:
Dates
Filing date:
30/08/2006
Grant date:
14/10/2009
EP publication date:
WO publication date:
Claims translation received date:
Translation received date (EP publication B1):
13/01/2010
Translation received date (EP publication B2):
Translation received date (EP publication B3):
Registration date:
14/10/2009
EP B1 publication date:
14/10/2009
EP B2 publication date:
EP B3 publication date:
Lapsed date:
Expiration date (if granted and all annual fees paid):
30/08/2026
Revocation Date:
24/10/2012
Applicant
1
Name:
Merck Sharp & Dohme Corp.
Legal Form:
From:
02/08/2012
Address:
126 East Lincoln Avenue, Rahway New Jersey 07065, United States (US)
To:
2
Name:
The Government of the United states of America as represented by The Secretary of The department of Health and Human Services
Legal Form:
From:
02/08/2012
Address:
National Institutes of Health Office of Technology Transfer Suite 325 6011 Executive Boulevard, Rockville MD 20852-3804, United States (US)
To:
3
Name:
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
Legal Form:
From:
14/10/2009
Address:
-, -, Unknown (UNKNOWN)
To:
02/08/2012
4
Name:
SCHERING CORP.
Legal Form:
From:
14/10/2009
Address:
-, -, Unknown (UNKNOWN)
To:
02/08/2012
Agent
Name:
de KEMMETER François
Legal Form:
From:
13/01/2010
Address:
Boulevard Général Wahis 15, 1030, BRUXELLES, Belgium (BE)